Emergent BioSolutions (EBS) Accounts Payables (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Accounts Payables of $39.5 million for Q1 2026, down 32.01% year-over-year from $58.1 million in Q1 2025, and down 28.96% quarter-over-quarter from $55.6 million in Q4 2025.
Emergent BioSolutions (EBS) Accounts Payables (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Accounts Payables history runs 17 years deep, the most recent figure standing at $39.5 million for Q1 2026.
- In Q1 2026, Accounts Payables fell 32.01% year-over-year to $39.5 million; the TTM figure through Mar 2026 stood at $39.5 million (down 32.01% YoY), while the FY2025 annual figure was $55.6 million, down 8.7% from the prior year.
- Accounts Payables for Q1 2026 stood at $39.5 million, down from $55.6 million in the prior quarter.
- The five-year high for Accounts Payables was $124.2 million in Q1 2023, with the low at $39.5 million in Q1 2026.
- The 5-year median for Accounts Payables is $100.2 million (2024), against an average of $87.6 million.
- The sharpest annual moves came in 2023 and 2024: Accounts Payables grew 15.75% in 2023, then tumbled 45.72% in 2024.
- Emergent BioSolutions' Accounts Payables stood at $103.5 million in 2022, then increased by 8.41% to $112.2 million in 2023, then slumped by 45.72% to $60.9 million in 2024, then decreased by 8.7% to $55.6 million in 2025, then declined by 28.96% to $39.5 million in 2026.
- Business Quant data shows EBS's Accounts Payables at $39.5 million in Q1 2026, $55.6 million in Q4 2025, and $57.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -5.09 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 2.72 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 452.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 2.80 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 497.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.73 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 808.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 427.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 356.00 Mn |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 50.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.20 Mn |
| Mar 31, 2026 | 39.50 Mn |
| Dec 31, 2025 | 55.60 Mn |
| Sep 30, 2025 | 57.40 Mn |
| Jun 30, 2025 | 63.70 Mn |
| Mar 31, 2025 | 58.10 Mn |
| Dec 31, 2024 | 60.90 Mn |
| Sep 30, 2024 | 82.10 Mn |
| Jun 30, 2024 | 95.90 Mn |
| Mar 31, 2024 | 100.20 Mn |
| Dec 31, 2023 | 112.20 Mn |
| Sep 30, 2023 | 112.70 Mn |
| Jun 30, 2023 | 108.30 Mn |
| Mar 31, 2023 | 124.20 Mn |
| Dec 31, 2022 | 103.50 Mn |
| Sep 30, 2022 | 101.00 Mn |
| Jun 30, 2022 | 106.20 Mn |
| Mar 31, 2022 | 107.30 Mn |
| Dec 31, 2021 | 128.90 Mn |
| Sep 30, 2021 | 135.20 Mn |